Drug intelligence / Profile preview

C1199B

Development stage: Preclinical
Lead developer: CasInvent Pharma
Modality: Small Molecules

Overview

C1199B is a selective small-molecule inhibitor of Casein Kinase 1 (CK1) being developed by CasInvent Pharma. It is specifically targeted toward the treatment of neurodegenerative disorders, including Huntington's Disease, Amyotrophic Lateral Sclerosis (ALS), and Parkinson's Disease (PD). The Casein Kinase 1 family of serine/threonine kinases is involved in various cellular processes such as DNA repair and circadian rhythms, and its dysregulation has been implicated in the pathogenesis of central nervous system (CNS) diseases. CasInvent Pharma, a spin-off from Masaryk University, plans to partner this candidate with CNS-focused pharmaceutical companies for further clinical development.

Targets

CSNK1G3 (Casein kinase 1 gamma 3)

Beyond the preview

Go deeper on C1199B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C1199B.

Explore the full profile